Auto-Immune/Inflammatory Diseases

Product	Indication	Status
Laquinimod	Crohn's disease Lupus Nephritis	Phase I/II Pre-Clinical
TV-3813	Psoriasis	Pre-clinical
Various other programs		Research

Laquinimod for Crohn's Disease and Lupus Nephritis

Laquinimod is an oral new chemical entity-a quinoline-3-carboxamide derivative. In addition to the efficacy that it has shown in Phase II clinical trials related to MS, laquinimod has demonstrated potent therapeutic efficacy in preclinical models of other autoimmune diseases such as rheumatoid arthritis, insulin-dependent diabetes mellitus, Guillain Barré Syndrome, lupus and Inflammatory Bowel Disease. The broad profile of efficacy in animal models of inflammatory diseases suggests that laquinimod affects a pivotal pathway of inflammation and autoimmunity. During 2008, Teva expects to initiate the clinical development of laquinimod for Crohn's disease and during 2009 for lupus nephritis.